华安国证生物医药ETF发起式联接C(012599)财务指标
| |
2024-06-30 |
2023-12-31 |
2023-06-30 |
2022-12-31 |
| 本期已实现收益 |
-7,107,196.09 |
-12,742,855.80 |
-1,406,431.68 |
-2,302,592.28 |
| 本期利润 |
-25,629,558.97 |
-584,356.62 |
-10,920,905.10 |
-4,728,541.36 |
| 加权平均基金份额本期利润 |
-0.18 |
0.00 |
-0.17 |
-0.18 |
| 本期加权平均净值利润率(%) |
-39.95 |
-0.77 |
-27.24 |
-25.74 |
| 本期基金份额净值增长率(%) |
-27.91 |
-2.69 |
-20.26 |
-25.79 |
| 期末可供分配利润 |
-82,455,014.29 |
-93,987,093.60 |
-49,316,075.35 |
-20,761,240.53 |
| 期末可供分配基金份额利润 |
-0.61 |
-0.45 |
-0.46 |
-0.32 |
| 期末基金资产净值 |
53,723,595.20 |
113,579,375.92 |
58,349,560.03 |
44,064,550.13 |
| 期末基金份额净值 |
0.39 |
0.55 |
0.54 |
0.68 |
| 基金份额累计净值增长率(%) |
-29.84 |
-2.69 |
-45.80 |
-32.03 |
微信公众号
证券之星APP
基本资料
